logo
welcome
Associated Press News

Associated Press News

Health

Health

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Associated Press News
Summary
Nutrition label

82% Informative

Eli Lilly and Co. shares slipped 1% to $ 831.64 Thursday in premarket trading.

Sales of diabetes and obesity treatments Mounjaro and Zepbound are soaring in popularity globally due to the amount of weight people lose while taking the injections.

For 2025 , Lilly expects adjusted earnings to range between $22.50 and $ 24 with revenue falling between $58 and $61 billion .

VR Score

89

Informative language

93

Neutral language

24

Article tone

formal

Language

English

Language complexity

40

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Source diversity

1

Affiliate links

no affiliate links